.jpeg)
2026-05-20 02:26:46
A comprehensive guide to Trifluridine/Tipiracil (FTD/TPI), an oral chemotherapy for metastatic colorectal and gastric cancers. Learn about safety profiles, bone marrow suppression, and clinical management strategies.
2026-05-20 02:14:35
Discover how Trelagliptin offers a breakthrough in Type 2 Diabetes management with its once-weekly dosing, superior adherence, stable glycemic control, and long-term safety profile.
2026-05-19 07:04:42
This article details the medication precautions and risk management strategies for the KRAS G12C targeted inhibitor Adagrasib in women of childbearing age, pregnant and lactating women, elderly patients, and patients with underlying comorbidities.
2026-05-18 04:21:15
Olutasidenib (Rezlidhia) is an oral IDH1 mutation inhibitor developed by Rigel Pharmaceuticals. Approved by the FDA in 2022, it is used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring IDH1 mutations. With definite efficacy and good tolerability, it provides a precise targeted treatment option for such patients.
2026-05-18 04:06:05
Capmatinib, a highly selective MET inhibitor, demonstrates transformative efficacy in METex14-mutated NSCLC. Pivotal GEOMETRY data show significant tumor shrinkage and survival improvement, particularly in brain metastases. Global accessibility through originator and generic options empowers patients, while ongoing combo therapies and resistance research expand future horizons.
2026-05-15 02:57:37
The FDA has granted approval to Teclistamab (Tecvayli) in combination with Daratumumab and hyaluronidase (Darzalex Faspro) for relapsed or refractory multiple myeloma (RRMM). Based on pivotal MajesTEC-3 data, this dual-targeted immunotherapy demonstrates transformative PFS and OS benefits, offering a new standard for heavily pretreated patients. This article dissects the mechanism, trial outcomes, safety profile, and clinical implications, providing actionable insights for global oncology teams.
2026-05-15 02:34:50
Beyond its traditional TKI role, Cabozantinib is reshaping cancer care as a core agent across RCC, RAI-R DTC, HCC, and NETs. This article dissects its expanding indications, synergistic combination strategies, side effect management, and global access dynamics, offering actionable insights for patients and clinicians in the Asia-Pacific and international communities.
2026-05-13 03:19:49
This article dissects the standard duration, long-term risks, and应对 strategies of Pretomanid (core component of BPaL regimen) for drug-resistant TB, highlighting the dangers of exceeding the recommended timeline and offering specialized guidance for patients who have used Pretomanid for three years.
2026-05-12 07:29:57
The SKYSCRAPER-02C study focuses on Chinese patients with extensive-stage small cell lung cancer (ES-SCLC), comparing the efficacy and safety of tiragolumab combination therapy versus standard treatment. Results demonstrate numerically improved PFS and OS with the combination, along with biomarker insights for personalized treatment.
2026-05-12 07:24:42
Research uncovers that lysophosphatidylcholine acyltransferase 3 (LPCAT3) plays a pivotal role in the progression of metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). Its deficiency promotes mitochondrial dysfunction and tumor formation, while overexpression reverses pathological processes, offering a novel therapeutic target.
2026-05-12 03:08:03
Tucatinib, an oral TKI developed by Seagen, selectively targets HER2 to inhibit cancer cell growth. Approved by FDA in 2020 for advanced HER2+ breast cancer (including brain metastases) and expanded to RAS-wildtype HER2+ CRC in 2023. This treatment, combined with trastuzumab and capecitabine, significantly prolongs survival and improves outcomes. This article details indications, dosing, precautions, and safety profiles for informed clinical use.
2026-05-12 02:17:51
Venetoclax, a BCL-2 inhibitor, demonstrates remarkable efficacy in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). However, its potency necessitates stringent safety protocols, particularly in managing tumor lysis syndrome (TLS), neutropenia, infections, and pregnancy risks. This article unpacks monitoring strategies and risk mitigation practices from global clinical guidelines to optimize treatment outcomes.
